City of Hope is a recognized leader in myeloma research with more than three decades of experience. Our research projects have been funded by the National Cancer Institute (NCI) and many other research-based organizations, and our scientists collaborate with other leading research institutions to develop tomorrow’s breakthroughs today.
City of Hope is also the only southern California center in the Multiple Myeloma Research Consortium (MMRC), a collaboration of multiple medical institutions across the nation with the goal of finding and advancing the most promising therapies against myeloma. Since its founding in 2004, MMRC have conducted over 30 clinical trials of more than 20 novel compounds and drug combinations. Patients treated at City of Hope may be able to access MMRC-facilitated trials of novel, potential drugs that can become tomorrow’s standard of care for myeloma.
In addition to MMRC-facilitated studies, City of Hope has its own extensive program of
myeloma clinical trials,
providing our patients access to novel therapies, including many that are not available elsewhere. We are a national leader in transplant trials and are heavily involved in new drug trials, including a recently approved novel agent (carfilzomib) for myeloma.
Developmental Therapeutics Program
has an active portfolio of trials for patients with recurrent myeloma, including trials of new chemotherapy and immunotherapy drugs, and we are one of the few institutions to begin T cell trials.
We are also actively involved in
to ensure that our patients lead full, productive lives following their myeloma diagnosis and treatments.